Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Metabolic Profiles Distinguish Early-Stage Ovarian Cancer with Unprecedented Accuracy

November 17, 2015 10:27 am | by Georgia Institute of Technology | News | Comments

Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer. Read more...


RNA-Based Drugs Give More Control Over Gene Editing

November 17, 2015 10:04 am | by UC San Diego | News | Comments

CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes. Read more...


Johnson & Johnson Multiple Myeloma Drug Wins Accelerated OK

November 17, 2015 9:59 am | by Linda Johnson, AP Business Writer | News | Comments

A Johnson & Johnson drug won Food and Drug Administration approval Monday for treating the incurable blood cancer multiple myeloma in patients who've failed prior therapies and have few options left. Read more...


Studies Show China Continues to Lag in Effective Tobacco Control

November 17, 2015 8:15 am | by University of Waterloo | News | Comments

China is the world’s largest producer and consumer of tobacco, with more than 300 million smokers. Read more...


Duchenne Muscular Dystrophy is a Stem Cell Disease

November 17, 2015 8:00 am | by Ottawa Hospital Research Institute | News | Comments

Muscle stem cells are responsible for muscle repair after normal injuries and exercise. Read more...


Mouth Cancer Now Tenth Most Common Cancer in Men

November 17, 2015 7:45 am | by Cancer Research UK | News | Comments

It is the fifteenth most common cancer in women. Read more...


New Analyses Further Support Efficacy, Safety Profile for Boehringer's OFEV in IPF

November 17, 2015 7:30 am | News | Comments

Treatment with OFEV in the real-world clinical setting showed a safety profile consistent with that observed in clinical trials supporting its approval by the FDA. Read more...


Big Data Driving Earlier Cancer Diagnosis in England

November 17, 2015 7:15 am | by Public Health England | News | Comments

Rates of survival for cancer patients diagnosed as an emergency are much lower than through other routes. Read more...


Simple Urine Test Could Diagnose HCV

November 17, 2015 7:00 am | by Ryan Bushey, Associate Editor | News | Comments

This method could significantly reduce the time and cost it takes to accurately diagnose the disease. Read more...


FDA Approves AstraZeneca's Metastatic EGFR Treatment

November 16, 2015 12:52 pm | News | Comments

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Read more...


10 Percent of Diabetes Cases Among Adults Aged 50+ are Undiagnosed

November 16, 2015 11:50 am | by Trinity College Dublin | News | Comments

New research shows that 10 percent of adults aged 50 and over in Ireland, the equivalent to 120,000 older adults, have type 2 diabetes, rising to 16 percent in those aged 80 and over. Read more...


Avanir: Initiation of Phase 3 Trial of AVP-786 for Agitation in Alzheimer’s

November 16, 2015 11:42 am | News | Comments

Avanir Pharmaceuticals, Inc. today announced initiation of enrollment into a phase 3 clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer’s disease. This is the first of two placebo-controlled phase 3 trials in the company’s TRIAD program. Read more...


Gilead's Zydelig Combination Shows Superior Efficacy in Phase 3 CLL Study

November 16, 2015 11:36 am | News | Comments

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. today announced that its Phase 3 Study 115 evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. Read more..


Alimera: 36-Month Analysis That Shows Iluvien Slows Diabetic Retinopathy

November 16, 2015 11:27 am | News | Comments

Alimera Sciences, Inc.(Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of patients from the FAME Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edema (DME) treated with Iluvien. Read more...


Child with Drug-Resistant TB Successfully Treated at Johns Hopkins Children's Center

November 16, 2015 9:41 am | by Johns Hopkins University | News | Comments

Johns Hopkins Children's Center specialists report they have successfully treated and put in remission a 2-year-old, now age 5, with a highly virulent form of tuberculosis known as XDR TB, or extensively drug-resistant TB. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.